Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation

被引：12

作者：

Borda, B. ^{[1
]}

Lengyel, Cs ^{[2
]}

Varkonyi, T. ^{[2
]}

Kemeny, E. ^{[3
]}

Ottlakan, A. ^{[1
]}

Kubik, A. ^{[4
]}

Keresztes, Cs ^{[5
]}

Lazar, Gy ^{[1
]}

机构：

[1] Univ Szeged, Dept Surg, Fac Med, H-6720 Szeged, Hungary

[2] Univ Szeged, Dept Internal Med 1, Fac Med, H-6720 Szeged, Hungary

[3] Univ Szeged, Inst Pathol, Fac Med, H-6720 Szeged, Hungary

[4] Semmelweis Univ, Fac Med, Dept Urol, H-1085 Budapest, Hungary

[5] Univ Szeged, Fac Med, Dept Med Translat & Commun, H-6720 Szeged, Hungary

来源：

ACTA PHYSIOLOGICA HUNGARICA | 2014年 / 101卷 / 03期

关键词：

calcineurin inhibitors; new-onset diabetes mellitus after kidney transplantation; protocol biopsy; RENAL-TRANSPLANTATION; MELLITUS; GLUCOSE; RISK;

D O I：

10.1556/APhysiol.101.2014.3.13

中图分类号：

学科分类号：

摘要：

New-onset diabetes after transplantation (NODAT) is one of the frequent complications following kidney transplantation. Patients were randomized to receive cyclosporine A-or tacrolimus-based immunosuppression. Fasting and oral glucose tolerance tests were performed, and the patients were assigned to one of the following three groups based on the results: normal, impaired fasting glucose/impaired glucose tolerance (IFG/IGT), or NODAT. NODAT developed in 14% of patients receiving cyclosporine A-based immunosuppression and in 26% of patients taking tacrolimus (p = 0.0002). Albumin levels were similar, but uric acid level (p = 0.002) and the age of the recipient (p = 0.003) were significantly different comparing the diabetic and the normal groups. Evaluation of tissue samples revealed that acute cellular rejection (ACR) and interstitial fibrosis/tubular atrophy (IF/TA) were significantly different in the NODAT group. The pathological effect of new-onset diabetes after kidney transplantation can be detected in the morphology of the renal allograft earlier, before the development of any sign of functional impairment.

引用

页码：388 / 394

页数：7

共 16 条

[1]

American Diabetes Association, 2010, DIABETES CARE S1, V33

[2]

Arif M, 2009, JCPSP-J COLL PHYSICI, V19, P627, DOI 10.2009/JCPSP.627631

[3] Functional and Histopathologic Changes in Renal Transplant Patients With New-Onset Diabetes and Dyslipidemia [J].

Borda, B. ;

Szederkenyi, E. ;

Lengyel, C. ;

Morvay, Z. ;

Eller, J. ;

Marofka, F. ;

Szabo, V. ;

Takacs, T. ;

Szenohradszky, P. ;

Hodi, Z. ;

Lazar, G. .

TRANSPLANTATION PROCEEDINGS, 2011, 43 (04) :1254-1258

[4]

Borda B, 2012, ACTA PHYSL HUNGARICA, V1, P101

[5] New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation [J].

Cosio, FG ;

Kudva, Y ;

van der Velde, M ;

Larson, TS ;

Textor, SC ;

Griffin, MD ;

Stegall, MD .

KIDNEY INTERNATIONAL, 2005, 67 (06) :2415-2421

[6] New-onset diabetes after transplantation: 2003 International Consensus Guidelines [J].

Davidson, J ;

Wilkinson, A ;

Dantal, J ;

Dotta, F ;

Haller, H ;

Hernández, D ;

Kasiske, BL ;

Kiberd, B ;

Krentz, A ;

Legendre, C ;

Marchetti, P ;

Markell, M ;

van der Woude, FJ ;

Wheeler, DC .

TRANSPLANTATION, 2003, 75 (10) :SS3-SS24

[7]

Gero L, 1995, DIABETOLOGIA HUNGARI, V3, P181

[8] Impact of glucose metabolism abnormalities on histopathological changes in kidney transplant protocol biopsies [J].

Helantera, Ilkka ;

Ortiz, Fernanda ;

Raisanen-Sokolowski, Anne ;

Koskinen, Petri .

TRANSPLANT INTERNATIONAL, 2010, 23 (04) :374-381

[9] Frequency and Risk Factors for Posttransplant Diabetes Mellitus in Iranian Renal Transplant Patients [J].

Ossareh, S. ;

Naseem, S. ;

Faraji, M. A. ;

Asl, M. Bahrami ;

Yousefnejad, A. .

TRANSPLANTATION PROCEEDINGS, 2009, 41 (07) :2814-2816

[10]

Racusen Lorraine C, 2004, Am J Transplant, V4, P1562, DOI 10.1111/j.1600-6143.2004.00585.x

← 1 2 →